D2 receptor

The D2 receptor (dopamine D2 receptor) is a G protein-coupled receptor that responds to dopamine — the brain's primary reward and motivation signal. It belongs to the D2-like receptor family, alongside the D3 and D4 subtypes, all of which share a broadly inhibitory character.

D2 receptors are concentrated in the striatum and nucleus accumbens (areas central to reward and habit), the limbic system (emotion), and the prefrontal cortex (cognition and working memory). A smaller population sits in the pituitary gland, where D2 activity suppresses prolactin release.

Because of its position at the heart of the dopamine reward circuit, the D2 receptor is one of the most clinically relevant targets in psychopharmacology.

How it works · its role

When dopamine binds the D2 receptor, it activates an inhibitory G protein (Gi), which suppresses the enzyme adenylyl cyclase. This reduces intracellular cyclic AMP and generally dampens the firing activity of the receiving neuron.

Crucially, D2 receptors also function as autoreceptors: when located on the same dopamine-releasing neuron, they act as a brake, sensing how much dopamine is already present in the synapse and throttling further release accordingly. This feedback loop helps the brain self-regulate dopamine tone.

The balance between D2 activation and blockade has large downstream effects — on motivation, motor control, and the subjective sense of reward or its absence.

Relevance to substances & effects

Antipsychotic drugs are the most direct example: virtually all of them work primarily by blocking D2 receptors, which reduces excess dopamine signalling thought to underlie the positive symptoms of psychosis (hallucinations, delusions). First-generation antipsychotics are dense D2 blockers; second-generation agents tend toward partial or more selective occupancy.

Stimulants — amphetamines, cocaine, and related drugs — do not act on D2 directly, but they flood the synapse with dopamine, overwhelming D2 and the wider reward circuit. The rush and reinforcement typical of stimulant use is largely a product of this surge.

LSD is notable in that it carries meaningful partial agonist activity at D2 (alongside its dominant 5-HT₂A action), a feature that may contribute to its unusual duration and the character of its cognitive effects compared with other psychedelics.

Dopamine agonists prescribed for Parkinson's disease and restless legs syndrome activate D2 directly, compensating for the loss of dopaminergic neurons in the substantia nigra.

Tolerance & dependence

With repeated, heavy stimulant use, the brain responds to the sustained dopamine excess by reducing D2 receptor density — a process called downregulation. Fewer receptors are available to respond to normal dopamine release, which blunts the reward circuit's sensitivity.

This is thought to underlie much of stimulant tolerance: the same dose produces less effect over time. During withdrawal and early abstinence, when dopamine tone is low and D2 density is still reduced, many people experience a flat, anhedonic mood — difficulty feeling pleasure from ordinary activities. Receptor density is generally thought to recover with sustained abstinence, though the timeline varies.